Can Aceminib cure chronic myelogenous leukemia?

Asciminib (Asciminib) is a new type of targeted therapy drug, mainly used to treat chronic myelogenous leukemia (CML) and other diseases caused by BCR-ABL gene mutations. The mechanism of action of Aceminib is different from traditional tyrosine kinase inhibitors (TKIs). It specifically targets the Abl kinase domain of the BCR-ABL protein, inhibiting its abnormal activity, thereby effectively inhibiting the growth of cancer cells. The drug is particularly effective for patients with CML who have developed resistance to traditional TKIs.

However, Asiminib cannot "radically cure" chronic myelogenous leukemia. Although it has shown good efficacy in clinical trials and can effectively control disease progression, alleviate symptoms, and achieve molecular remission in some patients, there is currently no evidence that it can completely cure CML. Chronic myeloid leukemia is a long-term chronic disease, and patients require continuous treatment to maintain the stability of the condition. While acemini can significantly improve patients' quality of life and extend survival, it does not completely eliminate the cause of the disease.

The goal of treating chronic myelogenous leukemia is to control the disease with drugs and keep patients in long-term remission. For patients taking aceminib, after achieving molecular remission, treatment still needs to be maintained for a period of time to prevent disease recurrence. Factors such as patient differences, disease progression, and drug tolerance will all affect the effectiveness of treatment. So while aceminib is a very promising drug, it currently remains a disease management drug, not a cure.

In clinical practice, aceminib, as a treatment option, can provide new treatment opportunities for some patients with chronic myelogenous leukemia, especially when traditional treatments fail or patients are resistant. Through individualized treatment plans, patients can achieve better disease control. However, patients should remain aware of the long-term nature of treatment, follow up regularly and adjust the treatment plan according to the development of the disease to obtain the best treatment effect.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib